When we first began offering orthopedic cellular therapy in 2005 as part of an IRB-approved medical study, we were one of the few clinics in the world treating orthopedic problems with cellular therapy. When we began treating everyday patients in 2007, this was still the case. Now other clinics are beginning to offer basic cell therapies, most in plastic surgery and cosmetics with a few clinics just starting to try orthopedic therapies. While we welcome the growth in cell-based medicine, we also know that we’re world leaders in this area. As leaders, we set a higher standard for ourselves in all of the cell-based procedures we offer our patients.

This Regenexx bone marrow-derived cellular treatment outcome data analysis is part of the Regenexx data download of patients who were tracked in the Regenexx advanced patient registry following treatment for Meniscus Tears.

This data utilizes LEFS (Lower Extremity Functional Scale) data from our knee arthritis patients treated with cellular injections. Functional questionnaires ask the patients questions, such as how well they can walk, run, climb stairs, etc. The improvements following the Regenexx Cellular Therapy are highly statistically significant.

This data looks at patient outcomes for cellular therapies for hip arthritis.

This outcome information summarizes the patient registry data for shoulders treated with the Regenexx same-day cellular therapy using the patient’s own cells. It was comprised of a mix of patients with rotator cuff tears, arthritis, labral tears, and instability.

This data was derived from a group of patients with mostly severe thumb arthritis who were injected with their own cells. Most of these patients would have been candidates for thumb joint replacement or a surgery where a tendon is coiled up in the joint at the base of the thumb. Both are big surgeries with significant complications.

This data analysis is part of the 2015 download of patient results tracked in our advanced treatment registry. The data shown here is predominantly for ankle patients that have, on average, moderate to severe arthritis with some also having instability in the ligaments and/or tendinitis/tendon tears. A few small foot joint patients are also included in this data set.

This outcome information summarizes the patient registry data for Regenexx platelet lysate spine procedures using platelet lysate (created from a patient’s own blood).

This data compares two groups of patients who received epidural steroids vs. PL-Disc and looks at their results at 3- and 6-month intervals using a Functional Rating Index (FRI), which measures things, like pain, as well as the ability to walk, sit, lift, bend, etc.

Regenexx has published more data on cellular therapy safety in peer-reviewed medical research for orthopedic applications than any other group worldwide. This is a report of 1,591 patients and 1,949 procedures treated with the Regenexx cellular therapy. Based on our analysis of this treatment registry data, the Regenexx cellular therapy is about as safe as any typical injection procedure, which is consistent with what we see every day in the clinic.

Hip data using Oxford Hip Scale to show pain and function.